MEI Pharma Reports Clinical Data On Oral CDK9 Inhibitor Voruciclib At ASH2023
– Safety Profile Observed to Date as Monotherapy and in Combination with Venetoclax Suggests no Overlapping Toxicity –– Initial Results from Correlative Studies Demonstrate On-target Reductions in Mcl-1 and RNA Pol II